期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 65, 期 25, 页码 2739-2746出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2015.04.059
关键词
cancer survivorship; cardiooncology; cardiovascular risk prevention; cardiovascular toxicity
资金
- National Institutes of Health
- Cell Therapeutics, Inc.
- Pfizer
- PA Cure Health
- Eisai
- Myriad
- National Cancer Institute
- University of South Florida
- [NIH/5KL2TR000102-04]
Many existing and emerging cancer therapies have a significant effect on the cardiovascular health of patients with cancer and cancer survivors. This paper examines current aspects of interdisciplinary cardio-oncology clinical care delivery and education in the United States and outlines how these data provide a platform for future development of the field. We present the results of the nationwide survey on cardio-oncology services, practices, and opinions, conducted among chiefs of cardiology and program directors, which demonstrate ranges of clinical activities and identify significant interest for increased educational opportunities and expert training of cardiovascular physicians in this field. The survey respondents recognized clinical relevance but emphasized lack of national guidelines, lack of funds, and limited awareness and infrastructure as the main challenges for development and growth of cardio-oncology. We discuss potential solutions to unmet needs through interdisciplinary collaboration and the active roles of professional societies and other stakeholders. (C) 2015 by the American College of Cardiology Foundation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据